New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanadelumab 150 mg/ml;   - solution for injection - 300 mg/2ml - active: lanadelumab 150 mg/ml   excipient: citric acid monohydrate dibasic sodium phosphate dihydrate histidine polysorbate 80 sodium chloride water for injection - takhzyro is indicated for routine prevention of recurrent attacks of hereditary angiodema (c1-esterase-inhibitor deficiency or dysfunction) in patients aged 12 years or older.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - agalsidase alfa 1 mg/ml (from human cell line);   - concentrate for infusion - 1 mg/ml - active: agalsidase alfa 1 mg/ml (from human cell line)   excipient: monobasic sodium phosphate monohydrate polysorbate 20 sodium chloride sodium hydroxide - replagal (agalsidase alfa ghu) is indicated for long-term enzyme replacement therapy of patients with fabry disease (alpha galactosidase a deficiency).

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - velaglucerase alfa 400 u;   - powder for infusion concentrate - 400 u - active: velaglucerase alfa 400 u   excipient: citric acid monohydrate polysorbate 20 sodium citrate dihydrate sucrose - vpriv is indicated for long-term enzyme replacement therapy (ert) for paediatric and adult patients with type i gaucher disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000 mg - chewable tablet - 1000 mg - active: lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000 mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 954mg equivalent to elemental lanthanum 500mg - chewable tablet - 500 mg - active: lanthanum carbonate hydrate 954mg equivalent to elemental lanthanum 500mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg - chewable tablet - 750 mg - active: lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000mg - powder for oral solution - 1000 mg - active: lanthanum carbonate hydrate 1908mg equivalent to elemental lanthanum 1000mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg - powder for oral solution - 750 mg - active: lanthanum carbonate hydrate 1431mg equivalent to elemental lanthanum 750mg excipient: colloidal silicon dioxide dextrates magnesium stearate - fosrenol is indicated in adult patients as a phosphate binding agent for use in the control of hyperphosphataemia in chronic renal failure patients on haemodialysis or continuous ambulatory peritoneal dialysis (capd). fosrenol is also indicated in adult patients with chronic kidney disease not on dialysis with serum phosphate levels above or equal to 1.78 mmol/l in whom a low phosphate diet alone is insufficient to control serum phosphate levels.

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 1000 [iu] - injection with diluent - 1000 iu - active: octocog alfa 1000 [iu] excipient: albumin calcium chloride dihydrate histidine hydrochloric acid macrogol 3350 sodium chloride sodium hydroxide water for injection - in haemophilia a (classical haemophilia) for the prevention and control of haemorrhagic episodes. · in the perioperative management of patients with haemophilia a (classical haemophilia).

New Zealand - English - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: albumin calcium chloride dihydrate histidine hydrochloric acid macrogol 3350 sodium chloride water for injection - in haemophilia a (classical haemophilia) for the prevention and control of haemorrhagic episodes. · in the perioperative management of patients with haemophilia a (classical haemophilia).